CORE
🇺🇦Â
 make metadata, not war
Services
Research
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
8 research outputs found
Randomized phase II study evaluating the efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload
Author
A. Kattamis
A. Taher
+6Â more
J.B. Porter
M.D. Cappellini
O. Schoenborn-Kellenberger
R. Pereno
T. Lawniczek
V. Viprakasit
Publication venue
W.B.Saunders
Publication date
01/11/2009
Field of study
No full text
AIR Universita degli studi di Milano
Factors associated with iron accumulation in non-transfusion-dependent thalassaemia syndromes : baseline data from multicenter international deferasirox study (THALASSA)
Author
A. Kattamis
A. Taher
+6Â more
J. Porter
M. D. Cappellini
O. Schoenborn- Kellenberger
R. Pereno
T. Lawniczeck
V. Viprakasit
Publication venue
Fondazione Ferrara Storti
Publication date
01/06/2010
Field of study
No full text
AIR Universita degli studi di Milano
UCL Discovery
Effets d'une perfusion unique d'acide zolédronique 5 mg versus risédronate (5 mg/jour) sur le remodelage osseux sur 1 an chez des patients avec ostéroporose cortisonique
Author
Chappard D.
COLLETTE Julien
+11Â more
Devogelaer J.
Eriksen E.
Ferreira A.
Goemaere S.
Ish-Shalom S.
Papanastasiou P.
Reginster Jean-Yves
Reid D.
Saag K.
Sambrook P.
Schoenborn-Kellenberger O.
Publication venue
Publication date
01/01/2008
Field of study
Full text link
Open Repository and Bibliography - Liège
Effects of a single 5 mg infusion of zoledronic acid and oral risedronate (5 mg/day) on bone remodeling over one year in patients with glucocorticoid-induced osteoporosis
Author
Chappard D.
Collette Julien
+12Â more
Devogelaer Jean-Pierre
Eriksen E. F.
Fashola T.
Ferreira A.
Goemaere S.
Ish-Shalom S.
Papanastasiou P.
Reginster Jean-Yves
Reid D. M.
Saag K. G.
Sambrook P.
Schoenborn-Kellenberger O.
Publication venue
Publication date
01/06/2008
Field of study
Full text link
Open Repository and Bibliography - Liège
Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis
Author
30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research
Devogelaer Jean-Pierre
+11Â more
Fashola T.
Lau C.
Maylandt K.
Mesenbrink P.
Papanastasiou P.
Reginster Jacques
Reid D.
Roux C.
Saag K.
Sambrook P.
Schoenborn-Kellenberger O.
Publication venue
Publication date
01/01/2008
Field of study
Full text link
Open Repository and Bibliography - Liège
DIAL UCLouvain
Effect of a single i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis.
Author
2nd Joint Meeting of the International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-Mineral-Society
Devogelaer Jean-Pierre
+11Â more
Fashola T.
Lau C.
Maylandt K.
Mesenbrink P.
Papanastasiou P.
Reginster Jacques
Reid D.
Roux C.
Saag K.
Sambrook P.
Schoenborn-Kellenberger O.
Publication venue
Publication date
01/01/2009
Field of study
Full text link
peer reviewe
Open Repository and Bibliography - Liège
DIAL UCLouvain
Effect of a aingle i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis
Author
2nd Joint Meeting of the International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-Mineral-Society
Devogelaer Jean-Pierre
+11Â more
Fashola T.
Lau C.
Maylandt K.
Mesenbrink P.
Papanastasiou P.
Reginster Jacques
Reid D.
Roux C.
Saag K.
Sambrook P.
Schoenborn-Kellenberger O.
Publication venue
'Elsevier BV'
Publication date
01/01/2009
Field of study
No full text
DIAL UCLouvain
Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Author
Cathomas R.
Feyerabend S.
+18Â more
Fizazi K.
Gillessen S.
Gnad-Vogt U.
Gruellich C.
Heidenreich A.
Hong H. S.
Klinkhardt U.
Koch S. D.
Kuebler H.
Loriot Y.
Perez Gracia S. L.
Reus V.
Sarosiek T.
Schoenborn-Kellenberger O.
Schroeder A.
Seibel T.
Stenzl A.
Syndikus I.
Publication venue
OXFORD UNIV PRESS
Publication date
01/01/2017
Field of study
No full text
Kölner UniversitätsPublikationsServer